All News

Certain immune cell types are associated with immune checkpoint inhibitor (ICI) response in patients with non–small cell lung cancer (NSCLC).

Data from the 1999-2018 National Health and Nutrition Examination Survey were used to analyze the prevalence of social determinants of health (SDOH) among patients with self-reported heart failure (HF).

Using rapid genome sequencing, researchers evaluate the impact of an expedited genetic diagnosis of infantile epilepsy.

Neil Goldfarb, president and CEO of the Greater Philadelphia Business Coalition on Health (GPBCH), previews the upcoming GPBCH Wellness Summit taking place on September 14, 2023.

The US Preventive Services Task Force (USPSTF) has recommended that clinicians prescribe pre-exposure prophylaxis (PrEP) to decrease the risk of acquiring HIV.

Novavax’s COVID-19 vaccine shows immunity against the Eris subvariant; infants with excessive screen time are at higher risk of developmental delays; a near-total abortion ban is expected to go into effect in Indiana within days.

Stephen Kingsmore, MD, DSc, shares the exciting advancement of the BeginNGS newborn genomic sequencing program as it approaches the end of phase 2.

The European Society of Cardiology (ESC) 2023 Congress runs August 25-28 in Amsterdam, the Netherlands.

The respiratory syncytial virus (RSV) vaccine Abrysvo is approved for use in pregnant individuals to prevent RSV in infants up to 6 months of age.

Variants associated with hidradenitis suppurativa (HS) near the SOX9 and KLF5 genes were associated with HS risk.

Individuals with a higher risk of primary open-angle glaucoma (POAG) could be identified using a polygenic risk score, recent study found.

About 17 million middle-class Americans have unpaid medical bills; more than 1 in 5 patients hospitalized with COVID-19 developed high blood pressure; work requirements for Supplemental Nutrition Assistance Program (SNAP) benefits to begin in September.

Sara Horst, MD, MPH, FACG, of Vanderbilt University Medical Center, discussed the recent digital health developments most beneficial to both patients and providers, as well as considerations around using these tools wisely.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discusses the difficulties inherent in making CRISPR gene editing technology an equitable treatment.

Gustavo Fonseca, MD, FACP, physician director of clinical research, Florida Cancer Specialists & Research Institute (FCS), discusses the results from a late phase complexity analysis on barriers to clinical trials regarding biopsy requirements.

The study also found people with vitamin D deficiency had a lower mortality rate from Clostridioides difficile infection (CDI).

Patients with non-small cell lung cancer (NSCLC) with a high risk of brain metastases might feasibly be identified through machine-learning models, according to a recent study.

The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) harboring a BRCA mutation.

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment failure compared with other PSA-based definitions.

This rare adverse effect was witnessed in a small number of people post vaccine administration.

In this multicenter cohort study, COVID-19 vaccination at any gestational stage improved antibody responses for pregnant individuals and their infants. Booster vaccine recipients demonstrated increased benefits in these effects at delivery.

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of time to treatment initiation.

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

The revisions to the ACO REACH model are expected to add predictability and stability while advancing health equity.

Researchers found that patients with chronic obstructive pulmonary disorder (COPD) with higher Systemic Immune-Inflammation Index (SII) levels have a greater risk of all-cause mortality.

Even patients with diffuse large B-cell lymphoma who are eligible for chimeric antigen receptor (CAR) T-cell therapy face multiple barriers to care and need assistance.

Despite receiving their diagnosis at a younger average age, Hispanic or Latino patients paradoxically have the lowest incidence of recent breast cancer screenings prior to diagnosis.